Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Operating Income (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Operating Income over the past 16 years, most recently at $5.3 million for Q2 2025.

  • For Q2 2025, Operating Income rose 147.88% year-over-year to $5.3 million; the TTM value through May 2025 reached -$17.2 million, down 95.01%, while the annual FY2025 figure was -$17.2 million, 94.99% down from the prior year.
  • Operating Income for Q2 2025 was $5.3 million at Lifecore Biomedical, Inc. \De\, up from -$9.0 million in the prior quarter.
  • Over five years, Operating Income peaked at $5.3 million in Q2 2025 and troughed at -$11.6 million in Q3 2024.
  • A 5-year average of -$3.3 million and a median of -$2.9 million in 2022 define the central range for Operating Income.
  • Biggest five-year swings in Operating Income: skyrocketed 301.78% in 2021 and later plummeted 13302.74% in 2022.
  • Year by year, Operating Income stood at $3.7 million in 2021, then plummeted by 245.04% to -$5.4 million in 2022, then surged by 72.29% to -$1.5 million in 2023, then plummeted by 32.1% to -$2.0 million in 2024, then skyrocketed by 371.92% to $5.3 million in 2025.
  • Business Quant data shows Operating Income for LFCR at $5.3 million in Q2 2025, -$9.0 million in Q1 2025, and -$2.0 million in Q4 2024.